SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Blue Jet Healthcare Ltd (BLUEJET)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 544009 NSE: BLUEJET Pharmaceuticals & Drugs | Small Cap | Blue Jet Healthcare Share Price

₹465.05 -10.75 (-2.26%)

As on 05-Jun'26 16:59

Blue Jet Healthcare Ltd (BLUEJET)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 544009 NSE: BLUEJET Pharmaceuticals & Drugs | Small Cap | Blue Jet Healthcare Share Price

₹465.05 -10.75 (-2.26%)

As on 05-Jun'26 16:59

Key Metrics
Valuation Multiples
Market Cap
₹8,253 Cr.
Current Price
₹465.1
52-Week Low / High
₹325 / 1,028
TTM EPS
₹14.3
TTM Sales
₹947 Cr.
Book Value per Share
₹78.4
P/E Ratio
33.30
In line with its 5-year historical median
Industry PE
46.5
Price to Book (P/B)
6.07
Higher than its 5-year historical median
Price to Sales (P/S)
8.71
In line with its 5-year historical median
EV/EBITDA
22.34
In line with its 5-year historical median
Dividend Yield
0.14%
Profitability Efficiency
Return on Equity (ROE)
30.85%
Outperforms industry median
Return on Capital Employed (ROCE)
41.06%
Outperforms industry median
Return on Assets (ROA)
21.22%
Operating Profit Margin
36.7%
Net Profit Margin
29.63%
Gross Profit Margin
41.2%
Growth Momentum
1-yr vs 3-yr growth
Sales Growth (1 Year)
Improving versus 3-year growth rate
44.74%
Operating Profit Growth (1 Year)
Improving versus 3-year growth rate
64.78%
Net Profit Growth (1 Year)
Improving versus 3-year growth rate
86.38%
Asset Quality
Promoter Holding
79.81%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹1,325 Cr.
Equity
₹34.7 Cr.
Face Value
₹2
All Time Low / High
₹319.40 / 1028.20

Blue Jet Healthcare stock performance

Key Ratios
mw4me loader

Check Before You Invest

Quality

Somewhat Good

Valuation

Fair

Price Trend

Strong
Q.1 Is Blue Jet Healthcare Ltd a good quality company?
Blue Jet Healthcare Ltd is a average quality company, based on a somewhat consistent multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

  • How has it performed on generating Profits?

    By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.

  • How efficiently has it utilized Capital?

    By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.

  • How is it managing its Debt?

    By checking its Debt to Equity and Cash Flow from Operations.

How does Blue Jet Healthcare Ltd performance compare with that of its Peers?
Q.1 Revenue growth of Blue Jet Healthcare Ltd vs industry peers?
Blue Jet Healthcare Ltd revenue CAGR is 0.00%, compared to the industry median CAGR of 5.35%, indicating slower growth and losing its market share.
Q.1 Promoter shareholding and pledge status of Blue Jet Healthcare Ltd?
Promoters hold 79.81% of the Blue Jet Healthcare Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Q.1 Stock return of Blue Jet Healthcare Ltd over the last decade?
Over the last 1 year(s), the stock has delivered a CAGR of -44.16% based on the current price.

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Blue Jet Healthcare Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation

Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % 50%54%36.2%28.9%41.1%-
Value Creation
Index
2.73.01.61.12.0-

Growth Parameters

Sales 4996837217121,030947
Sales YoY Gr.-37%5.5%-1.3%44.7%-
Adj EPS 7.99.88.69.416.514.3
YoY Gr.-23.9%-12.2%9.8%75.1%-
BVPS (₹) 19.630.139.348.765.378.4
Adj Net
Profit
137170149164287248
Cash Flow from Ops. 13514614224145.8-
Debt/CF from Ops. 0.40000-

CAGR

9 Years 5 Years 3 Years 1 Years
Sales NANA14.7%44.7%
Adj EPS NANA19.1%75.1%
BVPSNANA29.5%34%
Share Price - - - -48.5%

Key Financial Parameters

Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
40.339.424.821.52919.9
Op. Profit
Mgn %
41.536.530.432.436.731.1
Net Profit
Mgn %
27.524.920.72327.826.2
Debt to
Equity
0.200000
Working Cap
Days
0214260290270226
Cash Conv.
Cycle
0110138140133172

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'21Mar'22Mar'23Mar'24Mar'25
Sales4996837217121,030
Operating Expenses + 292434502482652
Manufacturing Costs5365685970
Material Costs169287336314461
Employee Cost 2933425361
Other Costs 4149565660
Operating Profit 207249219229378
Operating Profit Margin (%) 41.5%36.5%30.4%32.2%36.7%
Other Income + 919242946
Exceptional Items 000-100
Interest 53100
Depreciation 2022252818
Profit Before Tax 190243217220406
Tax 49625756101
Profit After Tax 142182160164305
PAT Margin (%) 28.4%26.6%22.2%23.0%29.6%
Adjusted EPS (₹)8.210.59.29.417.6
Dividend Payout Ratio (%)0%0%0%10.60%6.80%

Valuation of Blue Jet Healthcare - Standalone

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Analyst's Notes

data not found
No data found!

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund + 3405226818451,133
Share Capital 1035353535
Reserves 3304876478111,098
Debt +360000
Long Term Debt290000
Short Term Debt70000
Minority Interest00000
Trade Payables6057543089
Others Liabilities 158220271339440
Total Liabilities 5937981,0071,2141,662

Fixed Assets

Net Fixed Assets +139156151172300
Gross Block176215231276421
Accumulated Depreciation375880104121
CWIP 333014789
Investments 3794189250187
Inventories118105126130264
Trade Receivables144227239177350
Cash Equivalents 70886685120
Others Assets 83124205254353
Total Assets 5937981,0071,2141,662

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity + 13514614224146
PBT 190243217220406
Adjustment 1771819-8
Changes in Working Capital -73-76-3313-263
Tax Paid -0-28-60-11-89
Cash Flow From Investing Activity + -56-76-147-264-35
Capex -49-21-59-174-79
Net Investments -8-55-88-9139
Others 10005
Cash Flow From Financing Activity + -27-56-4-2-19
Net Proceeds from Shares 00000
Net Proceeds from Borrowing -8-29000
Interest Paid -5-4-1-0-0
Dividend Paid 0000-17
Others -14-23-3-2-1
Net Cash Flow 5114-10-24-8

Financial Ratio

PARTICULARSMar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)41.6742.1626.621.4530.85
ROCE (%)50.0354.0136.2428.8541.06
Asset Turnover Ratio0.840.980.80.640.72
PAT to CFO Conversion(x)0.950.80.891.470.15
Working Capital Days
Receivable Days105.4099.20118.20106.8093.30
Inventory Days86.1059.5058.4065.5069.80
Payable Days128.2073.7059.9048.8047.20

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Blue Jet Healthcare Ltd FAQs

The current trading price of Blue Jet Healthcare on 05-Jun-2026 16:59 is ₹465.1.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 04-Jun-2026 the market cap of Blue Jet Healthcare stood at ₹8,253.5 Cr

The latest P/E ratio of Blue Jet Healthcare as of 04-Jun-2026 is 33.30.

The latest P/B ratio of Blue Jet Healthcare as of 04-Jun-2026 is 6.07.

The 52-week high of Blue Jet Healthcare is ₹1,028.2 and the 52-week low is ₹325.2.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Blue Jet Healthcare is ₹947 ( Cr.) .

Past 10 year's financial track record analysis by Moneyworks4me indicates that Blue Jet Healthcare Ltd is a average quality company.

The key valuation ratios of Blue Jet Healthcare Ltd's currently when compared to its past seem to suggest it is in the Fair zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Blue Jet Healthcare Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

About Blue Jet Healthcare Ltd

The company was originally incorporated as ‘Jet Chemicals Private Limited,’ under the provisions of the Companies Act, 1956, at Mumbai, pursuant to a certificate of incorporation dated December 7, 1968, issued by the Registrar of Companies, Maharashtra at Mumbai. Pursuant to the company’s Shareholders’ resolution dated December 28, 2020, the name of the company was changed to ‘Blue Jet Healthcare Private Limited’, and a fresh certificate of incorporation dated December 30, 2020, was issued by the Registrar of Companies, Maharashtra at Mumbai. Subsequently, the company was converted into a public limited company, and pursuant to a special resolution of its Shareholders dated May 5, 2022, and the name of the company was changed to ‘Blue Jet Healthcare Limited’ A fresh certificate of incorporation was issued by Registrar of Companies, Maharashtra, at Mumbai on May 18, 2022. 

The company is a speciality pharmaceutical and healthcare ingredients and intermediates company, offering niche products targeted toward innovator pharmaceutical companies and multi-national generic pharmaceutical companies. Since its incorporation in 1968, it has established a contract development and manufacturing organization (CDMO) business model with specialized chemistry capabilities in contrast media intermediates and high intensity sweeteners, on the back of strategic and early investments in research and development (R&D) and manufacturing infrastructure. It has competencies and manufacturing capabilities in contrast media intermediates and high-intensity sweeteners, including saccharin and its salts. The company manufactures a range of products in-house, including the key starting intermediate and advanced intermediates, which allows it to control its production process for consistent quality and cost effectiveness.

The company has built a long-term customer base with innovator pharmaceutical companies and multi-national generic pharmaceutical companies, supported by committed multi-year contracts of up to five years. The company’s ‘Collaboration, Development, Manufacturing’ approach has been, and will continue to be, critical to its success and a key factor for growing its CDMO business. Its product capabilities across the pharmaceutical and healthcare categories have evolved with its customers’ needs, supported by its manufacturing capabilities and technology-driven product development. Its operations are primarily organized in three product categories: (i) contrast media intermediates, (ii) high intensity sweeteners, and (iii) pharma intermediates and active pharmaceutical ingredients (APIs).

Business area of the company

The company is a global, science-led, pharmaceutical company evolved as Strategic Partner for Collaboration, Development & Manufacturing of advance Pharmaceutical Intermediates and API. 

Key awards, accreditations or recognitions

  • 2014: The company was awarded a certification of registration by the United Registrar of Systems in recognition of its quality management system which complies with ISO 9001: 2015 and in recognition of its environmental management system which complies with ISO 14001:2015 standards.
  • 2021: The company was awarded a certification by BQSR Quality Assurance Private to certify that its Occupational Health and Safety Management System conformed with the requirements of ISO 45001:2018. 

Major events and milestones

  • 1968: Established as Jet Chemicals Private Limited in Shahad (Unit I) by the late Shri B L Arora.
  • 1970: Began manufacturing saccharin and its salts, which are high-intensity sweeteners.
  • 2000: Entered the x-ray contrast media sector, with a basic building block (5- NIPA).
  • 2002: Commenced the manufacturing of pharma intermediates and API.
  • 2003: Established Blue Circle Organics Private Limited (at Unit-II, Ambernath facility).
  • 2017: Commenced semi-automated manufacturing block for contrast media intermediate business.
  • 2019: Received USFDA Establishment Inspection Report of Blue Circle Organics Private Limited for Unit II.
  • 2019: As part of the company’s corporate restructure strategy, a merger between Blue Circle Organics Private Limited and Jet Chemicals Private Limited was undertaken to form Blue Jet Healthcare Private Limited.
  • 2020: Acquisition of brownfield site in Mahad on a leasehold basis (i.e., Unit III).
  • 2021: Acquisition of greenfield site in Ambernath on a leasehold basis (i.e., Unit IV).


You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×